Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer
| Autor: | Jana C. Precht, Werner Schroth, Pilar H. Saladores, Hiltrud Brauch, Matthias Schwab |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty Antineoplastic Agents Hormonal Anastrozole Breast Neoplasms Pharmacology Biomarkers Pharmacological Pathology and Forensic Medicine chemistry.chemical_compound Breast cancer Exemestane Internal medicine Nitriles Genetics medicine Humans Aromatase skin and connective tissue diseases Molecular Biology biology Aromatase Inhibitors business.industry Letrozole Triazoles medicine.disease Androstadienes Tamoxifen Cytochrome P-450 CYP2D6 Receptors Estrogen chemistry biology.protein Molecular Medicine Female Personalized medicine business Pharmacogenetics medicine.drug |
| Zdroj: | Expert Review of Molecular Diagnostics. 13:349-365 |
| ISSN: | 1744-8352 1473-7159 |
| DOI: | 10.1586/erm.13.26 |
| Popis: | Estrogen-receptor positive breast cancer accounts for 75% of diagnosed breast cancers worldwide. There are currently two major options for adjuvant treatment: tamoxifen and aromatase inhibitors. Variability in metabolizing enzymes determines their pharmacokinetic profile, possibly affecting treatment response. Therefore, prediction of therapy outcome based on genotypes would enable a more personalized medicine approach, providing optimal therapy for each patient. In this review, the authors will discuss the current evidence on the most important metabolizing enzymes in endocrine therapy, with a special focus on CYP2D6 and its role in tamoxifen metabolism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|